Drugs / RAIN-32
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05012397 | Nov 2021 → Oct 2023 | adrenal cortex carcinoma, cervical cancer, cholangiocarcinoma, gastric adenocarcinoma +9 | Rain Oncology Inc | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT04979442 | Jul 2021 → Oct 2023 | dedifferentiated liposarcoma | Rain Oncology Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAIN-32 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04979442 ↗ |
| Route | Oral | “260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle” NCT04979442 ↗ |